PILL SLOWS MS BRAIN DAMAGE
THE world’s first daily “wonderpill” to treat MS is even more powerful than previously thought.
A trial has shown it not only cuts the risk of an MS attack, it can also slow brain shrinkage, which otherwise can
occur in patients at three times the normal rate.
The drug, Gilenya or fingolimod, is already available on the NHS and is revolutionising the lives of many of the
UK’s 100,000 multiple sclerosis patients, who face symptoms such as blurred vision and problems walking and
speaking.
Data presented at the European Committee for Treatment and Research
in Multiple Sclerosis congress, showed the drug cut the risk of an attack by up to 60 per cent and brain shrinkage by 35 to 39 per cent.
Gavin Giovannoni, Professor of Neurology at Barts and the London NHS Trust, said the “important” research
occur in patients at three times the normal rate.
The drug, Gilenya or fingolimod, is already available on the NHS and is revolutionising the lives of many of the
UK’s 100,000 multiple sclerosis patients, who face symptoms such as blurred vision and problems walking and
speaking.
Data presented at the European Committee for Treatment and Research
in Multiple Sclerosis congress, showed the drug cut the risk of an attack by up to 60 per cent and brain shrinkage by 35 to 39 per cent.Gavin Giovannoni, Professor
of Neurology at Barts and the London NHS Trust, said the “important” research
Posts
No comments:
Post a Comment